A5332: Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE)

Study Location:

BaltimoreIndiaWashington

Topic:

Cardiovascular Disease and HIV

Clinicaltrials.gov Link:

https://clinicaltrials.gov/ct2/show/NCT02344290?term=a5332&rank=1

IRB#:

Pro00011068

Coordinator:

Anna Wimpelberg (Washington)

Ilene Wiggins, RN (Baltimore)

Nishi Suryavanshi (India)

Enrollment:

Open

Trial Period:

Ongoing

REPRIEVE (A5332) is a large double-blind, randomized, placebo-controlled study of pitavastatin or placebo for about 72 months. The trial is testing the effect of statin therapy on preventing heart disease and death in HIV-infected persons on HIV medications who do not meet guidelines for starting statins.       

  • HIV infected men and women between the ages of 40 and 75
  • On HIV medications for at least 6 months
  • CD4 cell count greater than 100
  • No history of cardiovascular disease, such as heart attack, stroke, etc.
  • No history of cancer in the last 3 years
  • Not currently using a statin drug

Anna Wimpelberg (Washington)
202-797-3589
awimpelberg@whitman-walker.org


​Ilene Wiggins, RN (Baltimore)
410-614-2766
iwiggin1@jhmi.edu

Categories

Location
Topic

Clinical Trials

HPTN 078: Enhancing Recruitment, Linkage to Care and...

The purpose of this study is to develop and assess the efficacy of an integrated strategy that includes feasible and scalable...

Read More

A5253: Sensitivity and Specificity of Mycobacterium...

An estimated 3 million HIV-infected individuals will enter programs for antiretroviral (ARV) treatment in the coming year, with...

Read More

A5290, A Randomized, Phase 2b Study of a Double-Dose...

Rifampin (RIF), the cornerstone of TB treatment, has very problematic drug-drug interactions with PIs. The use of relatively...

Read More

A5314: Effect of LDMTX on Inflammation in HIV-infected...

A5314 is a phase II randomized, double-blind, placebo-controlled 36-week trial that will examine the safety and efficacy of...

Read More

A5324: A Randomized, Double-Blinded, Placebo-Controlled...

ACTG A5324 is a phase IV randomized, double-blinded, placebo-controlled study to assess the efficacy of adding Maraviroc (MVC)...

Read More